Advances in mobilization for the optimization of autologous stem cell transplantation

Julie Marie Vose, Anthony D. Ho, Bertrand Coiffier, Paolo Corradini, Issa Khouri, Anna Sureda, Koen Van Besien, John Dipersio

Research output: Contribution to journalReview article

42 Citations (Scopus)

Abstract

In autologous stem cell transplantation, mobilized peripheral blood has replaced the bone marrow as the preferred source of hematopoietic stem cells (HSCs). Because HSCs normally exist in the blood in very low numbers, the use of agents to "âmobilize"â HSCs from the marrow niche to the peripheral blood is essential for successful transplantation. Until recently, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor were the only approved agents by the US Food and Drug Administration for use as peripheral blood stem cell (PBSC)-mobilizing agents in the United States, but G-CSF has become the gold standard. Unfortunately, some patients fail to mobilize sufficient numbers of PBSCs for transplantation in response to G-CSF with or without chemotherapy. Recently, a new agent, plerixafor (AMD3100) added to G-CSF has been approved to enhance PBSC mobilization. This review will discuss the current methodologies to improve hematopoietic stem cell mobilization.

Original languageEnglish (US)
Pages (from-to)1412-1421
Number of pages10
JournalLeukemia and Lymphoma
Volume50
Issue number9
DOIs
StatePublished - Dec 1 2009

Fingerprint

Stem Cell Transplantation
Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cells
Hematopoietic Stem Cell Mobilization
Transplantation
Bone Marrow
Stem Cell Niche
United States Food and Drug Administration
Granulocyte-Macrophage Colony-Stimulating Factor
Drug Therapy
JM 3100
Peripheral Blood Stem Cells

Keywords

  • Autologous stem cell transplantation
  • peripheral blood stem cell transplantation
  • peripheral blood stem cells

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Vose, J. M., Ho, A. D., Coiffier, B., Corradini, P., Khouri, I., Sureda, A., ... Dipersio, J. (2009). Advances in mobilization for the optimization of autologous stem cell transplantation. Leukemia and Lymphoma, 50(9), 1412-1421. https://doi.org/10.1080/10428190903096701

Advances in mobilization for the optimization of autologous stem cell transplantation. / Vose, Julie Marie; Ho, Anthony D.; Coiffier, Bertrand; Corradini, Paolo; Khouri, Issa; Sureda, Anna; Van Besien, Koen; Dipersio, John.

In: Leukemia and Lymphoma, Vol. 50, No. 9, 01.12.2009, p. 1412-1421.

Research output: Contribution to journalReview article

Vose, JM, Ho, AD, Coiffier, B, Corradini, P, Khouri, I, Sureda, A, Van Besien, K & Dipersio, J 2009, 'Advances in mobilization for the optimization of autologous stem cell transplantation', Leukemia and Lymphoma, vol. 50, no. 9, pp. 1412-1421. https://doi.org/10.1080/10428190903096701
Vose, Julie Marie ; Ho, Anthony D. ; Coiffier, Bertrand ; Corradini, Paolo ; Khouri, Issa ; Sureda, Anna ; Van Besien, Koen ; Dipersio, John. / Advances in mobilization for the optimization of autologous stem cell transplantation. In: Leukemia and Lymphoma. 2009 ; Vol. 50, No. 9. pp. 1412-1421.
@article{d68c0c2d8afc448d89133ec24b2b9808,
title = "Advances in mobilization for the optimization of autologous stem cell transplantation",
abstract = "In autologous stem cell transplantation, mobilized peripheral blood has replaced the bone marrow as the preferred source of hematopoietic stem cells (HSCs). Because HSCs normally exist in the blood in very low numbers, the use of agents to {"}{\^a}mobilize{"}{\^a} HSCs from the marrow niche to the peripheral blood is essential for successful transplantation. Until recently, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor were the only approved agents by the US Food and Drug Administration for use as peripheral blood stem cell (PBSC)-mobilizing agents in the United States, but G-CSF has become the gold standard. Unfortunately, some patients fail to mobilize sufficient numbers of PBSCs for transplantation in response to G-CSF with or without chemotherapy. Recently, a new agent, plerixafor (AMD3100) added to G-CSF has been approved to enhance PBSC mobilization. This review will discuss the current methodologies to improve hematopoietic stem cell mobilization.",
keywords = "Autologous stem cell transplantation, peripheral blood stem cell transplantation, peripheral blood stem cells",
author = "Vose, {Julie Marie} and Ho, {Anthony D.} and Bertrand Coiffier and Paolo Corradini and Issa Khouri and Anna Sureda and {Van Besien}, Koen and John Dipersio",
year = "2009",
month = "12",
day = "1",
doi = "10.1080/10428190903096701",
language = "English (US)",
volume = "50",
pages = "1412--1421",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Advances in mobilization for the optimization of autologous stem cell transplantation

AU - Vose, Julie Marie

AU - Ho, Anthony D.

AU - Coiffier, Bertrand

AU - Corradini, Paolo

AU - Khouri, Issa

AU - Sureda, Anna

AU - Van Besien, Koen

AU - Dipersio, John

PY - 2009/12/1

Y1 - 2009/12/1

N2 - In autologous stem cell transplantation, mobilized peripheral blood has replaced the bone marrow as the preferred source of hematopoietic stem cells (HSCs). Because HSCs normally exist in the blood in very low numbers, the use of agents to "âmobilize"â HSCs from the marrow niche to the peripheral blood is essential for successful transplantation. Until recently, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor were the only approved agents by the US Food and Drug Administration for use as peripheral blood stem cell (PBSC)-mobilizing agents in the United States, but G-CSF has become the gold standard. Unfortunately, some patients fail to mobilize sufficient numbers of PBSCs for transplantation in response to G-CSF with or without chemotherapy. Recently, a new agent, plerixafor (AMD3100) added to G-CSF has been approved to enhance PBSC mobilization. This review will discuss the current methodologies to improve hematopoietic stem cell mobilization.

AB - In autologous stem cell transplantation, mobilized peripheral blood has replaced the bone marrow as the preferred source of hematopoietic stem cells (HSCs). Because HSCs normally exist in the blood in very low numbers, the use of agents to "âmobilize"â HSCs from the marrow niche to the peripheral blood is essential for successful transplantation. Until recently, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor were the only approved agents by the US Food and Drug Administration for use as peripheral blood stem cell (PBSC)-mobilizing agents in the United States, but G-CSF has become the gold standard. Unfortunately, some patients fail to mobilize sufficient numbers of PBSCs for transplantation in response to G-CSF with or without chemotherapy. Recently, a new agent, plerixafor (AMD3100) added to G-CSF has been approved to enhance PBSC mobilization. This review will discuss the current methodologies to improve hematopoietic stem cell mobilization.

KW - Autologous stem cell transplantation

KW - peripheral blood stem cell transplantation

KW - peripheral blood stem cells

UR - http://www.scopus.com/inward/record.url?scp=77952921898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952921898&partnerID=8YFLogxK

U2 - 10.1080/10428190903096701

DO - 10.1080/10428190903096701

M3 - Review article

C2 - 19603345

AN - SCOPUS:77952921898

VL - 50

SP - 1412

EP - 1421

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -